Background: COVID-19 patients present with delirium during their hospitalization.

Aims: To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors.

Methods: COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales.

Results: Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006).

Discussion: The use of LMWH was associated with absence of delirium, independently of comorbidities and age.

Conclusions: The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664586PMC
http://dx.doi.org/10.1007/s10072-020-04887-4DOI Listing

Publication Analysis

Top Keywords

covid-19 patients
20
delirium
9
low molecular
8
molecular weight
8
weight heparin
8
patients delirium
8
patients
7
covid-19
5
heparin covid-19
4
patients prevents
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!